Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what steps her Department is taking to improve the availability of tactile paving on platform edges at train stations.
Answered by Keir Mather - Parliamentary Under-Secretary (Department for Transport)
All stations in England now have platform edge safety tactiles installed. The final station in Scotland is currently scheduled to have them installed by the end of December and the final station in Wales, currently closed for rebuilding, will have tactiles in place when it reopens in April 2026.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of offering CT scans to former miners.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
No assessment has been made on the potential merits of offering computed tomography (CT) scans to former miners. As set out in the recently published Men’s Health Strategy for England, we will expand the existing Respiratory Pathways Transformation Fund initiative by investing an additional £1 million this year through the Oxfordshire Health Innovation Network to develop targeted case-finding initiatives in former coalfield areas, such as those with chronic obstructive pulmonary disease. This will help us to identify the individuals who need support to access appropriate local services. Investigations such as CT scans will be considered for those reporting symptoms in areas in which we are targeting support, if clinically appropriate.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of cancer patients who could not afford to continue using their anticancer agent beyond its NHS availability.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.
These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.
NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:
https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussion
The Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that people who cannot afford anticancer treatment will continue to receive treatment beyond the stopping date of their anticancer agent being available on the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.
These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.
NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:
https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussion
The Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to ensure anticancer agents can be offered on the NHS for the duration of people’s cancer treatment.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.
These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.
NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:
https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussion
The Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the adequacy of systems for determining the duration of NHS funding for anticancer agents.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.
These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.
NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:
https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussion
The Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of making pembrolizumab available on the NHS for longer than two years.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based recommendations on whether new licensed medicines should be routinely funded by the National Health Service based on an assessment of clinical and cost effectiveness. The NHS in England is legally required to fund medicines in line with NICE’s recommendations.
These are very difficult decisions to make, and it is right that they are taken independently and on the basis of the evidence. NICE’s methods and processes for making its recommendations are internationally respected and have been developed through extensive consultation. NICE is able to recommend the vast majority of new licensed medicines for use on the NHS, and many thousands of patients have benefited from access to medicines as a result.
NICE’s guidance on the use of pembrolizumab for the treatment of untreated PD-L1-positive metastatic non-small-cell lung cancer recommends that treatment should be stopped at two years. This recommendation was based on the best available clinical evidence and was made in the interest of patient safety. During the development of guidance, NICE’s appraisal committee was informed by clinical experts that the optimal duration of treatment was unknown and, despite the medicine having low toxicity, long courses of intravenous infusion may be a burden to patients. Further information is set out in paragraph 3.6 of NICE’s published guidance at the following link:
https://www.nice.org.uk/guidance/ta531/chapter/3-Committee-discussion
The Department and NHS England do not hold any data on the number of patients who are unable to self-fund treatment of medicines beyond any stopping rule set out in NICE’s guidance.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve care for people with motor neurone disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs.
At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit. NHS England has also established a Neurology Transformation Programme, a multi-year, clinically-led programme, which has developed a new model of integrated care to support integrated care boards to deliver the right service, at the right time for all neurology patients, including those with MND.
In August 2025, NHS England updated its service specification for specialised adult neurology services. The service specification outlines that specialised neurology centres must include services for neuromuscular disorders, including MND. Service specifications define the standards of care expected from organisations funded by NHS England to provide specialised care.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support research into motor neurone disease.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Government responsibility for delivering research into motor neurone disease (MND) is shared between the Department of Health and Social Care, with research delivered via the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation, and Technology, with research delivered via UK Research and Innovation (UKRI) and the Medical Research Council for MND.
The Government is investing in MND research across a range of areas, including an £8 million investment via the NIHR into the EXPERTS-ALS. This is a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis (ALS): the most common form of MND.
The MND Translational Accelerator, supported by £6 million of Government funding, is connecting the UK Dementia Research Institute, the UK MND Research Institute and Dementias Platform UK. Twelve projects have been funded through the Accelerator; all aimed at speeding up the development of treatments for MND.
The NIHR and UKRI continue to welcome funding applications for research into MND.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Home Office:
To ask the Secretary of State for the Home Department, what steps she is taking to make (a) streets and (b) communities safer for women and girls.
Answered by Jess Phillips - Parliamentary Under-Secretary (Home Office)
Tackling violence against women and girls (VAWG) is a top priority for this Government with a manifesto mission to halve violence against women and girls in a decade. We will deliver a cross-government transformative approach, underpinned by a new strategy which we aim to publish as soon as possible.
In advance of the strategy, we have already introduced measures designed to strengthen the police response to VAWG, protect victims and hold perpetrators to account.
These include: funding to rollout Drive Project, a proven intervention for high-risk and high-harm domestic abuse perpetrators across England and Wales; embedding the first domestic abuse specialists in 999 control rooms in five police forces; measures to tackle spiking to strengthen the law and improve the response victims receive, including committing to introducing a new criminal offence for spiking and piloting new spiking training for bar staff; measures focusing on preventing and tackling ‘honour’-based abuse (HBA), developing a statutory definition for HBA, community engagement campaigns, enhanced training and funding for support services; six measures to tackle stalking including statutory guidance to empower the police to release the identities of online stalkers to protect victims, and a review of the stalking legislation to ensure it is fit for purpose; and launching the new Domestic Abuse Protection Orders in selected police forces and courts which go further than any existing orders.